Retrospective Observational Study to Compare the Short, Mid- and Long-term Prognosis and Outcomes of SRAS-CoV-2 Infected Hospitalized Patients With Cardiovascular Disease (CVD) to SARS-CoV-2 Infected Hospitalized Patients Without CVD: The Geneva Covid-19 CVD Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,927
- 试验地点
- 1
- 主要终点
- mortality discharge
研究概览
简要总结
In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.
详细描述
Hypothesis:
COVID-19+ hospitalized patients with preexisting CVD or newly onset CVD at time of hospitalization have different clinical outcomes compared to those without CVD and COVID-19+.
Objectives:
The primary aim of this study is to gather observational data, starting from February 1st 2020 until the end of the pandemic, to compare clinical outcomes COVID+ hospitalized patients at HUG or in a care center in Geneva with pre-existing or newly onset CVD, to COVID+ hospitalized patients at HUG or in a care center in Geneva without pre-existing CVD.
The secondary aims of this study are:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥18 years of age.
- •Patient diagnosed SARS-CoV-2 positive at time of hospitalization.
- •In case of the subject accepting the follow-up at 30 days and 1 year, Signed Patient Informed Consent (PIC) form
排除标准
- •Patients unwilling to provide informed consent for the follow-up.
结局指标
主要结局
mortality discharge
时间窗: 0 days after hospitalization
To compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD.
mortality 30 days after hospitalization
时间窗: 30 days after hospitalization
To comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD.
mobidity discharge
时间窗: 0 days after hospitalization
To compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD.
mobidity at 30 days
时间窗: 30 days after hospitalization
To compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD.
mortality 1 year after hospitalization
时间窗: 1 year after hospitalization
To compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD.
mobidity 1 year after hospitalization
时间窗: 1 year after hospitalization
To compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD.
次要结局
- Cost of hospital stay(0 days after hospitalization)
- Clinical outcomes according to medication at admission(1 year after hospitalization)
- Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).(30 days after hospitalization)
- Clinical outcomes related to preexisting cardiovascular risk factors at admission(1 year after hospitalization)
- New onset of CVD induced by COVID-19 disease(1 year after hospitalization)
- Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).(1 year after hospitalization)
研究者
François MACH
Professor François MACH
University Hospital, Geneva